Published in J Infect Dis on February 14, 2014
Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol (2016) 1.12
Macrophage-pathogen interactions in infectious diseases: new therapeutic insights from the zebrafish host model. Dis Model Mech (2014) 1.02
New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics. Immunol Rev (2015) 0.90
Protection and pathology in TB: learning from the zebrafish model. Semin Immunopathol (2015) 0.85
Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment? Ther Adv Chronic Dis (2015) 0.84
Membrane transport systems and the biodegradation potential and pathogenicity of genus Rhodococcus. Front Physiol (2014) 0.81
The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents. Antimicrob Agents Chemother (2014) 0.80
Targeting Energy Metabolism in Mycobacterium tuberculosis, a New Paradigm in Antimycobacterial Drug Discovery. MBio (2017) 0.80
Confinement-Induced Drug-Tolerance in Mycobacteria Mediated by an Efflux Mechanism. PLoS One (2015) 0.79
Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis. PLoS One (2016) 0.78
The Zebrafish Breathes New Life into the Study of Tuberculosis. Front Immunol (2016) 0.76
Tetrandrine reverses drug resistance in isoniazid and ethambutol dual drug-resistant Mycobacterium tuberculosis clinical isolates. BMC Infect Dis (2015) 0.75
New Verapamil Analogs Inhibit Intracellular Mycobacteria without Affecting the Functions of Mycobacterium-Specific T Cells. Antimicrob Agents Chemother (2015) 0.75
The stringent response factors PPX1 and PPK2 play an important role in Mycobacterium tuberculosis metabolism, biofilm formation, and sensitivity to isoniazid in vivo. Antimicrob Agents Chemother (2016) 0.75
Interplay between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium tuberculosis. Front Microbiol (2017) 0.75
Identification of novel antigen candidates for a tuberculosis vaccine in the adult zebrafish (Danio rerio). PLoS One (2017) 0.75
Efflux attenuates the anti-bacterial activity of Q203 in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2017) 0.75
Antimicrobial Activity and Resistance: Influencing Factors. Front Pharmacol (2017) 0.75
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science (2004) 13.04
Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis (1998) 11.56
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol (2009) 8.13
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature (2000) 7.66
The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med (2009) 5.78
Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc (1954) 5.58
Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc Natl Acad Sci U S A (2005) 4.43
M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) (2004) 4.38
Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J Clin Microbiol (1995) 3.60
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell (2011) 3.42
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med (2006) 3.20
Efflux-mediated drug resistance in bacteria: an update. Drugs (2009) 3.18
Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem (2008) 2.07
Why is long-term therapy required to cure tuberculosis? PLoS Med (2007) 2.03
Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med (2009) 2.03
Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med (2011) 1.87
Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit Rev Food Sci Nutr (2007) 1.87
A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother (2009) 1.74
Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a tap-like efflux pump. Infection (2004) 1.51
Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet (1972) 1.46
Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One (2012) 1.46
Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med (2009) 1.35
A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. PLoS One (2010) 1.32
Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother (2003) 1.30
Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog. Cardiovasc Res (1978) 1.29
Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism. Antimicrob Agents Chemother (2008) 1.29
Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med (2013) 1.23
J774 macrophages secrete antibiotics via organic anion transporters. J Infect Dis (1992) 1.20
Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis. J Antimicrob Chemother (2010) 1.16
Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2013) 1.12
Rv1218c, an ABC transporter of Mycobacterium tuberculosis with implications in drug discovery. Antimicrob Agents Chemother (2010) 1.05
Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache (2009) 1.04
Influence of piperine on rifampicin blood levels in patients of pulmonary tuberculosis. J Assoc Physicians India (1985) 1.02
Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis (Edinb) (2010) 1.02
Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates. Indian J Med Res (2011) 1.01
Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs (1989) 1.00
Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents (2010) 0.97
Inhibition of dihydrostreptomycin binding to Mycobacterium smegmatis by monovalent and divalent cation salts. Antimicrob Agents Chemother (1976) 0.92
Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study. Eur J Clin Pharmacol (2006) 0.89
Near-total reduction in verapamil bioavailability by rifampin. Electrocardiographic correlates. Chest (1988) 0.88
Reversal of multidrug resistance by verapamil analogues. Biochem Pharmacol (1995) 0.84
Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations. Curr Top Microbiol Immunol (2013) 0.83
Inhibitors of Ca2+ and K+ transport enhance intracellular killing of M. tuberculosis by non-killing macrophages. In Vivo (2008) 0.82
Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration. Drug Metab Dispos (2000) 0.77
Comparison of the pharmacokinetics of verapamil in the pregnant and non-pregnant rabbit: study of maternal and foetal tissue levels. Xenobiotica (2000) 0.77
Low-dose calcium pretreatment to prevent verapamil-induced hypotension. Am Heart J (1992) 0.77
Steady state verapamil tissue distribution in the dog: differing tissue accumulation. Pharmacology (1986) 0.76